News
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma delivered ... the most recent guidance provided in August, which projected revenue growth of 9-11% (CER) and adjusted EBITDA margin of 6-8%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback